Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Patent
1978-07-31
1980-04-22
Brown, Johnnie R.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
536 9, 536 17A, 26034341, A61K 3170, C07H 1708
Patent
active
041995694
ABSTRACT:
Derivatives of C-076 are described in which the C-076 molecule, as series of macrolides, has a specific unsaturation, at the 22,23-position, catalytically reduced. Further reaction of the reduced C-076 compounds are also possible. The compounds thus produced have profound anthelmintic, insecticidal, ectoparasiticidal and acaracidal activity. Compositions containing the described C-076 derivatives as the active ingredient thereof are also disclosed.
REFERENCES:
patent: 3853842 (1974-12-01), Kishi et al.
patent: 3950360 (1976-04-01), Aoki et al.
Chem. Abstract Cit. 86 (1977), 42838k.
Mishima, H. et al., Tetrahedron Letters, 10, pp. 711-714 (1975).
Journal of Antibiotics, 29(g), 1976, pp. 76-34, 76-42, 76-14, 76-16.
Chabala John C.
Fisher Michael H.
Brown Johnnie R.
Hazel Blondel
Merck & Co. , Inc.
Rose David L.
Westlake Harry E.
LandOfFree
Selective hydrogenation products of C-076 compounds and derivati does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective hydrogenation products of C-076 compounds and derivati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective hydrogenation products of C-076 compounds and derivati will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1475376